Details of the Drug

General Information of Drug (ID: DMDSWAG)

Drug Name
Methylphenobarbital
Synonyms
Enfenemal; Enphenemal; Enphenemalum; Mebaral; Meberal; Mebroin; Mephobarbital; Mephobarbitone; Mephytal; Methylphenobarbitalum; Methylphenobarbitone; Methylphenobarbitonum; Methylphenolbarbital; Metilfenobarbital; Metilfenobarbitale; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal; Prominaletten; Prominalum; Mephobarbital [JAN]; Methyl phenobarbitone; Methylphenylbarbituric acid; Metilfenobarbitale [DCIT]; Sanofi Brand of Mephobarbital; Sanofi Synthelabo Brand of Mephobarbital; Isonal (roussel); Mebaral (TN); Menta-Bal; Methyl-calminal; Methylphenobarbital (INN); Methylphenobarbitalum [INN-Latin]; Metilfenobarbital [INN-Spanish]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Mephobarbital (JAN/USP); N-Methyl-5-phenyl-5-ethylbarbital; 1-Methyl-5-ethyl-5-phenylbarbituric acid; 1-Methyl-5-phenyl-5-ethylbarbituric acid; 1-Methylphenobarbital; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric acid; 5-Ethyl-5-phenyl-N-methyl-bartituric acid; 5-Ethyl-N-methyl-5-phenylbarbituric acid; 5-Phenyl-5-ethyl-3-methylbarbituric acid; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Approved [1]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 246.26
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The oral absorption of drug is approximately 50% [2]
Bioavailability
73% of drug becomes completely available to its intended biological destination(s) [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 34 (range 11 - 67) hours [4]
Metabolism
The drug is metabolized via the hepatic [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 40.60615 micromolar/kg/day [5]
Chemical Identifiers
Formula
C13H14N2O3
IUPAC Name
5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
Canonical SMILES
CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2
InChI
InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
InChIKey
ALARQZQTBTVLJV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
8271
ChEBI ID
CHEBI:6758
CAS Number
115-38-8
DrugBank ID
DB00849
TTD ID
D08UMH
INTEDE ID
DR1026

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [6], [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [8]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methylphenobarbital (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Increased metabolism of Methylphenobarbital caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [33]
Midostaurin DMI6E0R Moderate Increased metabolism of Methylphenobarbital caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [34]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Methylphenobarbital caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [35]
Oliceridine DM6MDCF Major Increased metabolism of Methylphenobarbital caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [36]
Emapalumab DMZG5WL Moderate Altered metabolism of Methylphenobarbital due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [37]
Metronidazole DMTIVEN Moderate Increased metabolism of Methylphenobarbital caused by Metronidazole mediated induction of CYP450 enzyme. Amoebiasis [1A36] [38]
Siltuximab DMGEATB Moderate Altered metabolism of Methylphenobarbital due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [37]
Ivabradine DM0L594 Moderate Increased metabolism of Methylphenobarbital caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [39]
Dronedarone DMA8FS5 Moderate Increased metabolism of Methylphenobarbital caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [40]
Nifedipine DMSVOZT Moderate Increased metabolism of Methylphenobarbital caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [41]
Bedaquiline DM3906J Moderate Increased metabolism of Methylphenobarbital caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [42]
Aminophylline DML2NIB Moderate Increased metabolism of Methylphenobarbital caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [43]
Tindamax DM3OWT4 Moderate Increased metabolism of Methylphenobarbital caused by Tindamax mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [38]
Telithromycin DMZ4P3A Moderate Increased metabolism of Methylphenobarbital caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Cariprazine DMJYDVK Moderate Increased metabolism of Methylphenobarbital caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [39]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Methylphenobarbital caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Lapatinib DM3BH1Y Moderate Increased metabolism of Methylphenobarbital caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
LY2835219 DM93VBZ Moderate Increased metabolism of Methylphenobarbital caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Exemestane DM9HPW3 Moderate Increased metabolism of Methylphenobarbital caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [46]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Methylphenobarbital caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Tucatinib DMBESUA Moderate Increased metabolism of Methylphenobarbital caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Palbociclib DMD7L94 Moderate Increased metabolism of Methylphenobarbital caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Alpelisib DMEXMYK Moderate Increased metabolism of Methylphenobarbital caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Methylphenobarbital caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Methylphenobarbital caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
Bosutinib DMTI8YE Moderate Increased metabolism of Methylphenobarbital caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Atorvastatin DMF28YC Moderate Increased metabolism of Methylphenobarbital caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [52]
Macitentan DMP79A1 Moderate Increased metabolism of Methylphenobarbital caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [53]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Methylphenobarbital caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [54]
Corticotropin DMP9TWZ Moderate Increased metabolism of Methylphenobarbital caused by Corticotropin mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [55]
PF-04449913 DMSB068 Moderate Increased metabolism of Methylphenobarbital caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [56]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Methylphenobarbital and Dihydrocodeine. Chronic pain [MG30] [57]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Methylphenobarbital when combined with Levomilnacipran. Chronic pain [MG30] [58]
Anisindione DM2C48U Major Increased metabolism of Methylphenobarbital caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [59]
Drospirenone DM1A9W3 Moderate Increased metabolism of Methylphenobarbital caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [47]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Methylphenobarbital caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [47]
Ulipristal DMBNI20 Moderate Increased metabolism of Methylphenobarbital caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [39]
Levobupivacaine DM783CH Minor Increased metabolism of Methylphenobarbital caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [60]
Methoxyflurane DML0RAE Moderate Increased metabolism of Methylphenobarbital caused by Methoxyflurane mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [61]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Methylphenobarbital and Remifentanil. Corneal disease [9A76-9A78] [57]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Methylphenobarbital caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [43]
Osilodrostat DMIJC9X Moderate Increased metabolism of Methylphenobarbital caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [35]
Ivacaftor DMZC1HS Moderate Increased metabolism of Methylphenobarbital caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [62]
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Methylphenobarbital and Ethanol. Cystitis [GC00] [63]
MK-8228 DMOB58Q Moderate Increased metabolism of Methylphenobarbital caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [35]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Methylphenobarbital caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [64]
Sertraline DM0FB1J Moderate Antagonize the effect of Methylphenobarbital when combined with Sertraline. Depression [6A70-6A7Z] [65]
Vilazodone DM4LECQ Moderate Antagonize the effect of Methylphenobarbital when combined with Vilazodone. Depression [6A70-6A7Z] [65]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Methylphenobarbital when combined with Vortioxetine. Depression [6A70-6A7Z] [58]
Milnacipran DMBFE74 Moderate Antagonize the effect of Methylphenobarbital when combined with Milnacipran. Depression [6A70-6A7Z] [65]
Escitalopram DMFK9HG Moderate Antagonize the effect of Methylphenobarbital when combined with Escitalopram. Depression [6A70-6A7Z] [65]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Methylphenobarbital when combined with Desvenlafaxine. Depression [6A70-6A7Z] [65]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Methylphenobarbital and Esketamine. Depression [6A70-6A7Z] [66]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Methylphenobarbital caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [47]
Zonisamide DM0DTF7 Moderate Increased metabolism of Methylphenobarbital caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Cenobamate DMGOVHA Moderate Decreased metabolism of Methylphenobarbital caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [68]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Methylphenobarbital caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [69]
Praziquantel DMOU1PK Moderate Increased metabolism of Methylphenobarbital caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [70]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Methylphenobarbital caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [71]
Tazemetostat DMWP1BH Moderate Increased metabolism of Methylphenobarbital caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [72]
Solifenacin DMG592Q Moderate Increased metabolism of Methylphenobarbital caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [35]
Mirabegron DMS1GYT Minor Increased metabolism of Methylphenobarbital caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [73]
Ripretinib DM958QB Moderate Increased metabolism of Methylphenobarbital caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [48]
Sunitinib DMCBJSR Moderate Increased metabolism of Methylphenobarbital caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [48]
Avapritinib DMK2GZX Moderate Increased metabolism of Methylphenobarbital caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [39]
Carvedilol DMHTEAO Moderate Increased metabolism of Methylphenobarbital caused by Carvedilol mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [74]
Digitoxin DMWVIGP Moderate Increased metabolism of Methylphenobarbital caused by Digitoxin mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [75]
Boceprevir DMBSHMF Moderate Increased metabolism of Methylphenobarbital caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [76]
Telaprevir DMMRV29 Moderate Increased metabolism of Methylphenobarbital caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [76]
Rifampin DMA8J1G Minor Increased metabolism of Methylphenobarbital caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [77]
MK-1439 DM215WE Moderate Increased metabolism of Methylphenobarbital caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Methylphenobarbital caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Fostemsavir DM50ILT Minor Increased metabolism of Methylphenobarbital caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Tipranavir DM8HJX6 Moderate Increased metabolism of Methylphenobarbital caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Dolutegravir DMCZGRE Minor Increased metabolism of Methylphenobarbital caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Saquinavir DMG814N Moderate Increased metabolism of Methylphenobarbital caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Etravirine DMGV8QU Moderate Increased metabolism of Methylphenobarbital caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Methylphenobarbital caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Darunavir DMN3GCH Moderate Increased metabolism of Methylphenobarbital caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Atazanavir DMSYRBX Moderate Increased metabolism of Methylphenobarbital caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Maraviroc DMTL94F Moderate Increased metabolism of Methylphenobarbital caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [48]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Methylphenobarbital caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [48]
Paricalcitol DMYBV3G Moderate Increased metabolism of Methylphenobarbital caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [54]
Acebutolol DM0TI4U Moderate Increased metabolism of Methylphenobarbital caused by Acebutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [74]
Penbutolol DM4ES8F Moderate Increased metabolism of Methylphenobarbital caused by Penbutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [74]
Nebivolol DM7F1PA Moderate Increased metabolism of Methylphenobarbital caused by Nebivolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [74]
Levamlodipine DM92S6N Moderate Increased metabolism of Methylphenobarbital caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [41]
Felodipine DMOSW35 Moderate Increased metabolism of Methylphenobarbital caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Tolvaptan DMIWFRL Moderate Increased metabolism of Methylphenobarbital caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [39]
Lesinurad DMUR64T Moderate Increased metabolism of Methylphenobarbital caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [60]
Suvorexant DM0E6S3 Moderate Increased metabolism of Methylphenobarbital caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Methylphenobarbital caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
ITI-007 DMUQ1DO Major Increased metabolism of Methylphenobarbital caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [85]
Naloxegol DML0B41 Moderate Increased metabolism of Methylphenobarbital caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [86]
Pemigatinib DM819JF Moderate Increased metabolism of Methylphenobarbital caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [87]
Crizotinib DM4F29C Moderate Increased metabolism of Methylphenobarbital caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [82]
Brigatinib DM7W94S Moderate Increased metabolism of Methylphenobarbital caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [48]
Ceritinib DMB920Z Moderate Increased metabolism of Methylphenobarbital caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [88]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Methylphenobarbital caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [89]
Osimertinib DMRJLAT Moderate Increased metabolism of Methylphenobarbital caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Capmatinib DMYCXKL Moderate Increased metabolism of Methylphenobarbital caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [51]
Selpercatinib DMZR15V Moderate Increased metabolism of Methylphenobarbital caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Artemether DM48QOT Moderate Increased metabolism of Methylphenobarbital caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [48]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Methylphenobarbital when combined with Hydroxychloroquine. Malaria [1F40-1F45] [48]
Idelalisib DM602WT Moderate Increased metabolism of Methylphenobarbital caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [90]
GDC-0199 DMH0QKA Moderate Increased metabolism of Methylphenobarbital caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [35]
IPI-145 DMWA24P Moderate Increased metabolism of Methylphenobarbital caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [91]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Methylphenobarbital caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [92]
Ibrutinib DMHZCPO Moderate Increased metabolism of Methylphenobarbital caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [39]
Ponatinib DMYGJQO Moderate Increased metabolism of Methylphenobarbital caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [48]
Vemurafenib DM62UG5 Moderate Increased metabolism of Methylphenobarbital caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [35]
Selumetinib DMC7W6R Moderate Increased metabolism of Methylphenobarbital caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [93]
LGX818 DMNQXV8 Moderate Increased metabolism of Methylphenobarbital caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [94]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Methylphenobarbital caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [47]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Methylphenobarbital and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [95]
Ubrogepant DM749I3 Moderate Increased metabolism of Methylphenobarbital caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [96]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Methylphenobarbital and Lasmiditan. Migraine [8A80] [66]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Methylphenobarbital caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [54]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Methylphenobarbital and Flibanserin. Mood disorder [6A60-6E23] [66]
Panobinostat DM58WKG Moderate Increased metabolism of Methylphenobarbital caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [35]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Methylphenobarbital and Thalidomide. Multiple myeloma [2A83] [66]
Nilotinib DM7HXWT Moderate Increased metabolism of Methylphenobarbital caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Methylphenobarbital caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [97]
Dasatinib DMJV2EK Moderate Increased metabolism of Methylphenobarbital caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [48]
Rolapitant DM8XP26 Moderate Increased metabolism of Methylphenobarbital caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [98]
Bupropion DM5PCS7 Moderate Increased metabolism of Methylphenobarbital caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [99]
Entrectinib DMMPTLH Moderate Increased metabolism of Methylphenobarbital caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [39]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Methylphenobarbital and Levomethadyl Acetate. Opioid use disorder [6C43] [57]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Methylphenobarbital and Apraclonidine. Optic nerve disorder [9C40] [100]
Olaparib DM8QB1D Moderate Increased metabolism of Methylphenobarbital caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [48]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Methylphenobarbital and Oxymorphone. Pain [MG30-MG3Z] [57]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Methylphenobarbital and Dezocine. Pain [MG30-MG3Z] [57]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Methylphenobarbital and Buprenorphine. Pain [MG30-MG3Z] [101]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Methylphenobarbital and Hydrocodone. Pain [MG30-MG3Z] [36]
Pimavanserin DMR7IVC Moderate Increased metabolism of Methylphenobarbital caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [35]
Macimorelin DMQYJIR Moderate Increased metabolism of Methylphenobarbital caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [35]
Lefamulin DME6G97 Moderate Increased metabolism of Methylphenobarbital caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [35]
Ergonovine DM0VEC1 Moderate Increased metabolism of Methylphenobarbital caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [48]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Methylphenobarbital caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [102]
Enzalutamide DMGL19D Moderate Increased metabolism of Methylphenobarbital caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [35]
Darolutamide DMV7YFT Moderate Increased metabolism of Methylphenobarbital caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [51]
Silodosin DMJSBT6 Moderate Increased metabolism of Methylphenobarbital caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [48]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Methylphenobarbital due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [37]
Apremilast DMTWS9E Moderate Increased metabolism of Methylphenobarbital caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [103]
Ixekizumab DMXW92T Moderate Altered metabolism of Methylphenobarbital due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [37]
Riociguat DMXBLMP Moderate Increased metabolism of Methylphenobarbital caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [104]
Everolimus DM8X2EH Moderate Increased metabolism of Methylphenobarbital caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [48]
Axitinib DMGVH6N Moderate Increased metabolism of Methylphenobarbital caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [105]
Temsirolimus DMS104F Moderate Increased metabolism of Methylphenobarbital caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [48]
Tocilizumab DM7J6OR Moderate Altered metabolism of Methylphenobarbital due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Canakinumab DM8HLO5 Moderate Altered metabolism of Methylphenobarbital due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Tofacitinib DMBS370 Moderate Increased metabolism of Methylphenobarbital caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [48]
Rilonacept DMGLUQS Moderate Altered metabolism of Methylphenobarbital due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Golimumab DMHZV7X Moderate Altered metabolism of Methylphenobarbital due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Dexamethasone DMMWZET Moderate Increased metabolism of Methylphenobarbital caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [55]
Sarilumab DMOGNXY Moderate Altered metabolism of Methylphenobarbital due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [37]
Quetiapine DM1N62C Moderate Increased metabolism of Methylphenobarbital caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [48]
Aripiprazole DM3NUMH Moderate Increased metabolism of Methylphenobarbital caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [106]
Avanafil DM75CXN Moderate Increased metabolism of Methylphenobarbital caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [107]
LDE225 DMM9F25 Moderate Increased metabolism of Methylphenobarbital caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [108]
Larotrectinib DM26CQR Moderate Increased metabolism of Methylphenobarbital caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
Methylprednisolone DM4BDON Moderate Increased metabolism of Methylphenobarbital caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [55]
Docetaxel DMDI269 Moderate Increased metabolism of Methylphenobarbital caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [109]
Trabectedin DMG3Y89 Moderate Increased metabolism of Methylphenobarbital caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [39]
Armodafinil DMGB035 Moderate Increased metabolism of Methylphenobarbital caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [110]
LEE011 DMMX75K Moderate Increased metabolism of Methylphenobarbital caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Methylphenobarbital caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [55]
Taxol DMUOT9V Moderate Increased metabolism of Methylphenobarbital caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Doxorubicin DMVP5YE Moderate Increased metabolism of Methylphenobarbital caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [112]
Fostamatinib DM6AUHV Moderate Increased metabolism of Methylphenobarbital caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [35]
Apixaban DM89JLN Moderate Increased metabolism of Methylphenobarbital caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [35]
Brilinta DMBR01X Moderate Increased metabolism of Methylphenobarbital caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [39]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Methylphenobarbital caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [113]
Sirolimus DMGW1ID Moderate Increased metabolism of Methylphenobarbital caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [48]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Methylphenobarbital caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [48]
Canagliflozin DMFRM1I Moderate Increased metabolism of Methylphenobarbital caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [48]
Saxagliptin DMGXENV Moderate Increased metabolism of Methylphenobarbital caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [51]
Linagliptin DMWFJTR Moderate Increased metabolism of Methylphenobarbital caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [35]
Elagolix DMB2C0E Moderate Increased metabolism of Methylphenobarbital caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [114]
Propafenone DMPIBJK Minor Increased metabolism of Methylphenobarbital caused by Propafenone. Ventricular tachyarrhythmia [BC71] [115]
⏷ Show the Full List of 180 DDI Information of This Drug

References

1 Drug information of Methylphenobarbital, 2008. eduDrugs.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
7 Effect of barbiturates on polyphosphoinositide biosynthesis and protein kinase C activity in synaptosomes. Neuropharmacology. 1989 Dec;28(12):1317-23.
8 A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.
9 Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics. 2004 Aug;14(8):549-56.
10 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
11 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
12 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
13 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
14 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
15 Drugs that may have potential CYP2B6 interactions.
16 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
17 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
18 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
19 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
20 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
21 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
22 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
23 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
24 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
25 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
26 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
27 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
28 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
29 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
30 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
31 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
32 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
33 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
34 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
35 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
36 Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
37 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
38 Gupte S "Phenobarbital and metabolism of metronidazole." N Engl J Med 308 (1983): 529. [PMID: 6823276]
39 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
41 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
42 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43 Bukowskyj M, Nakatsu K, Munt PW "Theophylline reassessed." Ann Intern Med 101 (1984): 63-73. [PMID: 6145380]
44 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
45 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
46 Product Information. Aromasin (exemestane) Pharmacia &amp Upjohn, Kalamazoo, MI.
47 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
48 Cerner Multum, Inc. "Australian Product Information.".
49 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
51 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
52 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
53 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
54 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
55 Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
56 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
58 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
59 Antlitz AM, Tolentino M, Kosai MF "Effect of butabarbital on orally administered anticoagulants." Curr Ther Res Clin Exp 10 (1968): 70-3. [PMID: 4967727]
60 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
61 Brodeur J, Paquin P, Authier L, Geadah D, Yamauchi M, Cote MG "Influence of phenobarbital pretreatment on methoxyflurane and sodium fluoride nephropathy in Fischer 344 Rats." Toxicol Appl Pharmacol 37 (1976): 349-61. [PMID: 982456]
62 Product Information. Orkambi (ivacaftor-lumacaftor). Vertex Pharmaceuticals, Cambridge, MA.
63 Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5. [PMID: 5929537]
64 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
65 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
66 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
67 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
68 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
69 Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354]
70 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
71 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
72 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
73 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
74 Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
75 Cardoso MT, Carvalhas ML. Effects of phenobarbital on digitoxin metabolism in guinea-pig liver slices. Xenobiotica. 1980;10(10):779-784. [PMID: 7456493]
76 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
77 Richter E, Breimer DD, Zilly W "Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents." Eur J Clin Pharmacol 17 (1980): 197-202. [PMID: 7363932]
78 Product Information. Pifeltro (doravirine). Merck &amp Company Inc, Whitehouse Station, NJ.
79 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
80 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
81 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
82 Cerner Multum, Inc. "Canadian Product Information.".
83 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
84 Product Information. Belsomra (suvorexant). Merck &amp Company Inc, Whitehouse Station, NJ.
85 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
86 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
87 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
88 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
89 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
90 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
91 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
92 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
93 Multum Information Services, Inc. Expert Review Panel.
94 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
95 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
96 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
97 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
98 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
99 James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
100 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
101 Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ "Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes." Drug Alcohol Depend 132 (2013): 580-6. [PMID: 23688843]
102 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
103 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
104 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
105 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
106 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
107 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
108 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
109 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
110 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
111 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
112 Product Information. Adriamycin PFS (doxorubicin). Pharmacia and Upjohn, Kalamazoo, MI.
113 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
114 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
115 Sams RA, Muir WW. Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res. 1988;49(2):245-249. [PMID: 3348533]